Stoke Therapeutics (STOK) EBT (2022 - 2025)
Historic EBT for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$39.6 million.
- Stoke Therapeutics' EBT fell 4992.43% to -$39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 13826.23%. This contributed to the annual value of -$88.7 million for FY2024, which is 1538.26% up from last year.
- Per Stoke Therapeutics' latest filing, its EBT stood at -$39.6 million for Q3 2025, which was down 4992.43% from -$23.5 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' EBT registered a high of $114.2 million during Q1 2025, and its lowest value of -$39.6 million during Q3 2025.
- Over the past 4 years, Stoke Therapeutics' median EBT value was -$25.7 million (recorded in 2024), while the average stood at -$16.3 million.
- The largest annual percentage gain for Stoke Therapeutics' EBT in the last 5 years was 53283.92% (2025), contrasted with its biggest fall of 4992.43% (2025).
- Quarter analysis of 4 years shows Stoke Therapeutics' EBT stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 270.92% to -$39.6 million in 2025.
- Its EBT stands at -$39.6 million for Q3 2025, versus -$23.5 million for Q2 2025 and $114.2 million for Q1 2025.